SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001144204-05-038745
Filing Date
2005-12-05
Accepted
2005-12-05 16:14:34
Documents
9
Period of Report
2005-12-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 v030910_8k.htm 8-K 61666
2 v030910_ex4-1.htm EX-4.1 132838
3 v030910_ex4-2.htm EX-4.2 8321
4 v030910_ex4-3.htm EX-4.3 7958
5 v030910_ex4-4.htm EX-4.4 187229
6 v030910_ex4-5.htm EX-4.5 111761
7 v030910_ex4-6.htm EX-4.6 98128
8 v030910_ex99-1.htm EX-99.1 15722
9 GRAPHIC logo.jpg GRAPHIC 27859
  Complete submission text file 0001144204-05-038745.txt   663889
Mailing Address 33 HARBOUR SQ STE 202 TORONTO ONTARIO CA A1 M5J 2G2
Business Address 33 HARBOUR SQ STE 202 TORONTO ONTARIO CANA A1 M5J 2G2 4163642551
GENEREX BIOTECHNOLOGY CORP (Filer) CIK: 0001059784 (see all company filings)

IRS No.: 820490211 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-25169 | Film No.: 051244361
SIC: 2834 Pharmaceutical Preparations